Materials and methods PubMed and EMBASE were searched using the following keywords:
locally advanced non-small cell lung cancer, unresectable non-small cell lung cancer …

Purpose Concurrent chemoradiotherapy is standard treatment for patients with stage III non–
small-cell lung cancer. Elderly patients may experience increased rates of adverse events …

OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT)
plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used …

Recent advances in systemic cytotoxic and molecularly targeted therapies coupled with
technologic strides in radiotherapy have the potential to improve outcomes for patients with …

Approximately a third of patients with newly diagnosed non-small cell lung cancer (NSCLC)
have locally or regionally advanced disease not amenable for surgical resection. Concurrent …

Background The reported decreasing benefit with increasing age from concurrent
chemoradiotherapy in head and neck cancer patients prompted this retrospective review …

Background Lung cancer is the leading cause of cancer deaths, having caused an
estimated 1.6 million deaths worldwide in 2012 [Ferlay J, Soerjomataram I, Dikshit R et al …

Purpose There are very little data available comparing outcomes of intensity-modulated
proton therapy (IMPT) to intensity-modulated radiation therapy (IMRT) in patients with locally …

In the field of radiotherapy (RT), the issues of total dose, fractionation, and overall treatment
time for non-small cell lung cancer (NSCLC) have been extensively investigated. There is …

BACKGROUND. The objective of this study was to assess the value of combined‐modality
therapy in elderly patients by comparing the differences in outcome between patients who …